Zacks Research Comments on Gilead Sciences FY2025 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Zacks Research lifted their FY2025 earnings estimates for shares of Gilead Sciences in a research report issued to clients and investors on Thursday, November 13th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $8.10 per share for the year, up from their previous forecast of $7.76. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share.

Other equities research analysts also recently issued research reports about the company. Rothschild & Co Redburn boosted their price objective on Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. BMO Capital Markets lifted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a report on Monday, October 20th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Cantor Fitzgerald reissued an “overweight” rating and issued a $135.00 price target on shares of Gilead Sciences in a report on Friday, October 31st. Finally, JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $129.13.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $125.02 on Monday. Gilead Sciences has a 1-year low of $86.08 and a 1-year high of $127.68. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm has a market capitalization of $155.11 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 0.81 and a beta of 0.32. The company’s 50-day moving average is $117.44 and its two-hundred day moving average is $112.88.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS.

Institutional Investors Weigh In On Gilead Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Trivium Point Advisory LLC boosted its stake in shares of Gilead Sciences by 1.1% in the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock worth $813,000 after buying an additional 83 shares during the last quarter. Binnacle Investments Inc raised its stake in Gilead Sciences by 11.8% during the third quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 83 shares in the last quarter. Rothschild Investment LLC increased its position in shares of Gilead Sciences by 1.9% during the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after purchasing an additional 84 shares during the last quarter. Hemington Wealth Management raised its position in Gilead Sciences by 9.3% in the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 85 shares during the period. Finally, Ignite Planners LLC increased its stake in Gilead Sciences by 1.1% in the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after buying an additional 86 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $354,240.00. Following the completion of the sale, the insider directly owned 110,193 shares of the company’s stock, valued at $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Deborah H. Telman sold 53,646 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total value of $6,590,411.10. Following the transaction, the executive vice president directly owned 43,676 shares of the company’s stock, valued at approximately $5,365,596.60. This trade represents a 55.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 94,646 shares of company stock valued at $11,311,286 in the last 90 days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.